The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
Open accessAbstract
Background Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
From CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis (2021) · cites this paper as [13]
Citations
Cites
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Self-citationTafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationSafety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Self-citationTafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citationGuideline of transthyretin-related hereditary amyloidosis for clinicians
Ando, Y., Coelho, T., Berk, J. L., Cruz, M. W., Ericzon, B.-G., Ikeda, S.-I., Lewis, W. D., Obici, L., Planté-Bordeneuve, V., Rapezzi, C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-31 · Cited by 719
Self-citationRepurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Self-citationSolomon, S. D., Adams, D., Kristen, A., Grogan, M., González-Duarte, A., Maurer, M. S., Merlini, G., Damy, T., Slama, M. S., Brannagan, T. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035831 · Cited by 462
Self-citationHereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
Adams, D., Koike, H., Slama, M., & Coelho, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0210-4 · Cited by 448
Self-citationCoelho, T., Maurer, M. S., & Suhr, O. B. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 339
Self-citation
Cited by
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Self-citationKittleson, M. M., Ruberg, F. L., Ambardekar, A. V., Brannagan, T. H., Cheng, R. K., Clarke, J. O., Dember, L. M., Frantz, J. G., Hershberger, R. E., Maurer, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.022 · Cited by 640
Self-citationCurrent approaches of nanomedicines in the market and various stage of clinical translation
Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.025 · Cited by 335
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Nanoparticles and siRNA: a new era in therapeutics?
Pérez-Carrión, M. D., Posadas, I., & Ceña, V. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107102 · Cited by 48
Metadata
- Authors
- Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., Conceição, I. M., Slama, M. S., Gillmore, J. D., Kyriakides, T., Ajroud-Driss, S., Waddington-Cruz, M., Mezei, M. M., Planté-Bordeneuve, V., Attarian, S., Mauricio, E., Brannagan, T. H., Ueda, M., Aldinc, E., Wang, J. J., White, M. T., Vest, J., Berber, E., Sweetser, M. T., Coelho, T., Vita, G., Rizzo, V., Russo, M., Mazzeo, A., Gentile, L., Berk, J. L., Brueckner, C., Lazzari, V., Wiesman, J., DeLong, D., Victory, J., Dalton, J., May, J., Gilmore, C., Attarian, S., Diallo, S., Delmont, E., Pouget, J., Verschueren, A., Grapperon, A.-M., Campana-Salort, E., Conceição, I. M., Lopes, A., Lamas, F., Neves, C., Castro, J., Pereira, P., Castro, I., Franco, A., Santos, M. O., de Azevedo Coutinho, C., Falcao de Campos, C., Coelho, T., Hipólito Reis, A., Correia, N., Perez, J. M., Martins da Silva, A., Alves, C., Cardoso, M., Valdrez, K., Monte, J. R., Pessoa, B., Guimaraes, N., Freitas, M., Ramalho, J., Ferreira, N., Kuzume, D., Tard, C., Waucquier, N., Rougeaux, I., Brice, S., Kasprzyk, E., Elrezzi, E., Meguig, S., Hachulla, E., Gauvain, C., Migaud-Chervy, M.-C., Deplanque, D., Jozefowicz, E., Lebellec, L., Adams, D., Balaya-Gouraya, L., Jehan Lacour, N., Bournane, H., Martin, N., Elabed, M., Sacko, N., Boubrit, Y., Gaouar, A., Rakotondratafika, F., Théaudin-Saliou, M., Cauquil-Michon, C., Labeyrie, C., Not, A., Al-Salameh, A., Lecoq, A.-L., Stephant, M., Echaniz-Laguna, A., Becquemont, L., Beaudonnet, G., Algalarrondo, V., Eliahou, L., Slama, M. S., Rousseau, A., Signate, A., Berthelot, E., Inamo, J., Planté-Bordeneuve, V., Vervoitte, L., Focseneanu, C., Gendre, T., Arrouasse, R., Ayache, S. S., Ernande, L., Le Corvoisier, P., Salhi, H., Choumert, A., Ehinger, V., Ruiz, J., Charlin, C., Megelin, T., Brannagan III, T. H., Fayerman, R., Kim, A., Paras, A., Gonzalez, L. J., Tsang, S., Wajnsztajn, F., Shije, J., Ulane, C., Kleyman, I., Weimer, L., Cioroiu, C., Lambrianides, S., Abu-Manneh, R., Zamba-Papanicolaou, E., Agathangelou, P., Leonidou, E., Tada, S., Fujita, A., Nagai, M., Ando, R., Hosokawa, Y., Yamanishi, Y., Overcash, J. S., Giardino, E., Boyer, L., Dang, L., Le, A., Nguyen, T., Giang, L., Sellers, P., Tran, L., Truong, N., Vinas, M., Hrkman, N., Miller, S., Nguyen, D., Smith, A., Pu, H., Li, S., Vuong, T., Dioso, H., Green, S., Lee, K., Chu, H., Waters, M., Coskun, D. J., Zepeda, K. A., O'Riordan, W., Obici, L., Cortese, A., Lozza, A., Merlini, G., Rosti, V., Sabatelli, M., Bisogni, G., Bernardo, D., Luigetti, M., Di Paolantonio, A., Guglielmino, V., Bisogni, G., Romano, A., Nienhuis, H., Bulthuis-Kuiper, J., Kristen, A. V., Gerk, O., Ulbricht, H., Taylor, L., Meyle, E., Kleinschmidt, N., Meyrath, D., Noe-Schwenn, S., Meng, U., Bauer, R., aus dem Siepen, F., Hein, S., Takahashi, T., Oshita, T., Koujin, Y., Neshige, S., Nezu, T., Segawa, A., Ueno, H., Morino, H., Campistol, J. M., Rodas Marin, L. M., Blasco Pelicano, J. M., Dávila, L. G., Palacios, M., Pytel Cordoba, V., Guerrero Sola, A., Horga, A., García Feijoo, J., Perez de Isla, L., Marques Júnior, W., Moscardini, M., Litcanov, D. C., Viera Lima, A. F., Rodrigues, L., Marques Coutinho, B., Moreira, C. L., Daccach Marques, V., Munoz Beamud, F., Gragera Martínez, Á., Borrachero, C., Losada López, I. A., Cisneros Barroso, E., Rodríguez Rodríguez, A., Sanz, M., Rigo Oliver, E., González Moreno, J., Gamez Martinez, J. M., Descals, C., Uson, M., Jose Vega, F., Figuerola, A., Montala, C., Waddington-Cruz, M., Dias da Silva, M., Gervais de Santa Rosa, R., Pinto, L. F., Pinto, M. V., Cardoso Berensztejn, A., Barroso, F., Lautre, A., Orellana, L. G., González-Duarte Briseño, M. A., Cárdenas-Soto, K., Jiménez López, B. P., Pérez-Castañeda, S. L., Cantú Brito, C. G., Rivera de la Parra, D., Hernandez Reyes, J. P., del Mar Saniger Alba, M., Criollo Mora, E., Parman, Y., Rezzan, K. J., Sahin, E., Serbest, N. G., Durmus, H., Cakar, A., Tugal Tutkun, N. I., Karamursel, S., Elitok, A., Sirin Inan, N. G., Altinkurt, E., Polydefkis, M., Ye, J., Allen, A. C., Chaudhry, V., Jarrett, R., Bressler, N., Burks, K. L., Liu, Q., Khoshnoodi, M., Judge, D. P., Vista, G., Shah, S. M., Hamaguchi, H., Oda, J., Fukase, E., Taniguchi, I., Oda, T., Endo, H., Shimomura, M., Katanazaka, K., Koto, S., Nakano, T., Scheid, C., Zueiter, A., Pester, L., Walter, D., Özdemir, B., Frenzel, L. F., Holtick, U., Oh, J., Kim, H. J., Shin, H. J., Choi, K., Yamashita, T., Ueda, M., Masuda, T., Misumi, Y., Ueda, A., Nakahara, K., Yorita, A., Tsuruhisa, S., Taniwaki, T., Harada, M., Moritaka, T., Sakurada, N., Mauricio, E. A., Baskin, A., Dimberg, E., Dispenzieri, A., Fonder, A., Hobbs, M., Russell, S. J., Dyck, P., Gonsalves, W., Leung, N., Witzig, T. E., Zeldenrust, S. R., Hwa, L., Kapoor, P., Kumar, S. K., Lin, Y., Lust, J. A., Rajkumar, V. S., Dingli, D., Gertz, M. A., Go, R., Hayman, S. R., Dalia, S., Carrillo, E., Gorevic, P., Mason, G., Chao, C.-C., Lee, M.-J., Su, J.-J., Hsieh, S.-T., Tsai, L.-K., Yeh, S.-J., Yang, C.-C., Ajroud-Driss, S. A.-D., Casey, P., Joslin, B. C., Freimer, M., Sankey, A., Kenepp, A., Heintzman, S., LoRusso, S., Hokezu, Y., Kim, B.-J., Kim, J., Lee, G. Y., Cho, E. B., Jeon, E.-S., Min, J.-H., Seok, J. M., Lee, H. L., Park, J. H., Sekijima, Y., Miyazawa, C., Kato, N., Kishida, D., Hineno, A., Kodaira, M., Yoshinaga, T., Miyahara, T., Imai, A., Matsumoto, K., Lin, K.-P., Lee, Y.-C., Wixner, J., Falk, M., Pilebro, B., Suhr, O., Lindqvist, P., Soderberg, K., Pedrosa-Domellöf, F., Anan, I., Nordh, E., Tournev, I., Zhelyazkova-Glaveeva, S., Cherneva, Z., Sarafov, S., Chamova, T., Cherninkova-Gopina, S., Schmidt, H. H., Friebel, F., Zibert, A., Mihailovic, N., Schubert, F., Vorona, E., Lahme, L., Huesing-Kabar, A., Schilling, M., Kabar, I., Gillmore, J. D., Martinez-Naharro, A., Chacko, L., Cohen, O., Law, S., Rezk, T., Lachmann, H. J., Quan, D., Blume, B., Dixon, S., Low, S. C., Chan, S. L., Lim, H. E. L., Goh, K. J., Mezei, M. M., Kraus, D., Jack, K., Wade, N. K., Lopate, G., Zwijack, B., Florence, J., Sommerville, R. B., Stewart, G., Ryder, J., Mekhael, L., Taylor, M., Suan, D., Wells, K., Stone, P., Wells, K., Itoya, A., Owusu-Sekyere, M., Thai, D., Chahine, I., Pedrosa, S., & Do, T. H. (.
- Affiliations
- University of Nicosia (CY)
- Alnylam Pharmaceuticals (United States) (US)
- Columbia University (US)
- Centro Hospitalar Lisboa Norte (PT)
- Inserm (FR)
- Mayo Clinic in Florida (US)
- Johns Hopkins University (US)
- Hôpital de la Timone (FR)
- Kumamoto University Hospital (JP)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- ORCID
- Kyriakides, Theodoros
- Aldinc, Emre
- White, Matthew T
- Vita, Giuseppe
- Rizzo, Vincenzo
- Russo, Massimo
- Mazzeo, Anna
- Gentile, Luca
- Wiesman, Janice
- Victory, Jennifer
- Verschueren, Annie
- Grapperon, Aude-Marie
- Castro, Isabel
- Franco, Ana
- Santos, Miguel Oliveira
- Alves, Cristina
- Pessoa, Bernardete
- Ramalho, Joana
- Kuzume, Daisuke
- Hachulla, Eric
- Deplanque, Dominique
- Not, Adeline
- Lecoq, Anne-Lise
- Becquemont, Laurent
- Beaudonnet, Guillemette
- Algalarrondo, Vincent
- Eliahou, Ludivine
- Rousseau, Antoine
- Inamo, Jocelyn
- Gendre, Thierry
- Arrouasse, Raphaele
- Ayache, Samar S.
- Ernande, Laura
- Choumert, Ariane
- Kim, Arreum
- Kleyman, Inna
- Cioroiu, Comana
- Lambrianides, Sakis
- Tada, Satoshi
- Nagai, Masahiro
- Hosokawa, Yuko
- Yamanishi, Yuki
- Overcash, J. Scott
- Nguyen, David
- Obici, Laura
- Cortese, Andrea
- Lozza, Alessandro
- Merlini, Giampaolo
- Rosti, Vittorio
- Sabatelli, Mario
- Luigetti, Marco
- Guglielmino, Valeria
- Nienhuis, Hans
- Hein, Selina
- Takahashi, Tetsuya
- Neshige, Shuichiro
- Nezu, Tomohisa
- Morino, Hiroyuki
- Campistol, Josep M
- Horga, Alejandro
- Rodrigues, Leonardo
- Moreira, Carolina Lavigne
- Pinto, Luiz Felipe
- Barroso, Fabio
- Serbest, Nail G
- Ye, Jing
- Chaudhry, Vinay
- Bressler, Neil
- Liu, Qingfeng
- Khoshnoodi, Mohammad
- Judge, Daniel P
- Shah, Syed Mahmood
- Hamaguchi, Hirotoshi
- Oda, Tetsuya
- Endo, Hironobu
- Katanazaka, Kimitaka
- Koto, Shusuke
- Nakano, Takahiro
- Scheid, Christof
- Holtick, Udo
- Oh, Jeeyoung
- Shin, Hyun Jin
- Choi, Kyomin
- Yamashita, Taro
- Masuda, Teruaki
- Misumi, Yohei
- Nakahara, Keiichi
- Fonder, Amie
- Russell, Stephen J
- Dyck, Peter
- Gonsalves, Wilson
- Leung, Nelson
- Witzig, Thomas E
- Kapoor, Prashant
- Kumar, Shaji K
- Lin, Yi
- Dingli, David
- Gertz, Morie A
- Go, Ronald
- Hayman, Suzanne R
- Dalia, Samir
- Chao, Chi-Chao
- Lee, Ming-Jen
- Su, Jen-Jen
- Hsieh, Sung-Tsang
- Tsai, Li-Kai
- Yeh, Shin-Joe
- Yang, Chih-Chao
- Freimer, Miriam
- Lee, Ga Yeon
- Cho, Eun Bin
- Jeon, Eun-Seok
- Min, Ju-Hong
- Seok, Jin Myoung
- Lee, Hye Lim
- Park, Jae Hong
- Sekijima, Yoshiki
- Kishida, Dai
- Hineno, Akiyo
- Kodaira, Minori
- Yoshinaga, Tsuneaki
- Matsumoto, Kazuhiko
- Lee, Yi-Chung
- Falk, Malin
- Suhr, Ole
- Lindqvist, Per
- Anan, Intissar
- Cherneva, Zheyna
- Chamova, Teodora
- Zibert, Andree
- Schubert, Friederike
- Vorona, Elena
- Schilling, Matthias
- Kabar, Iyad
- Chacko, Liza
- Cohen, Oliver
- Law, Steven
- Rezk, Tamer
- Lachmann, Helen J
- Low, Soon Chai
- Goh, Khean Jin
- Taylor, Mark
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 20
- Issue
- 1
- Pages
- 49-59
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W3106443431
- Cited by
- 158
- References
- 23
- Citations by year
- 2026: 9 · 2025: 29 · 2024: 28 · 2023: 41 · 2022: 32 · 2021: 18
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-02-01)
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 349 d)
- Locations
- The Lancet Neurology (acceptedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Alnylam Pharmaceuticals
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- hereditary transthyretin amyloidosis, patisiran, RNA interference therapy, prealbumin, polyneuropathy, long-term safety, long-term efficacy, quality of life, autonomic symptoms, cardiac stress, APOLLO trial, open-label extension, rare disease treatment
- MeSH terms
- Adult, Aged, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Polyneuropathies, Prealbumin, Severity of Illness Index, Outcome Assessment, Health Care, Amyloid Neuropathies, Familial, RNA, Small Interfering, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. https://app.cochat.ai/papers/10.1016/s1474-4422(20)30368-9
- The paper
- Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., Conceição, I. M., Slama, M. S., Gillmore, J. D., Kyriakides, T., Ajroud-Driss, S., Waddington-Cruz, M., Mezei, M. M., Planté-Bordeneuve, V., Attarian, S., . . . Do, T. H. (. (2021). Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(20)30368-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.